The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27211547.
- Also identified by DOI 10.1016/j.ebiom.2016.03.035 and PMC identifier 4856795.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The incidence of Alzheimer's disease (AD) is growing every day and finding an effective treatment is becoming more vital. Amyloid-β (Aβ) has been the focus of research for several decades. The recent shift in the Aβ cascade hypothesis from all Aβ to small soluble oligomeric intermediates is directing the search for therapeutics towards the toxic mediators of the disease. Targeting the most toxic oligomers may prove to be an effective treatment by preventing their spread. Specific targeting of oligomers has been shown to protect cognition in rodent models. Additionally, the heterogeneity of research on Aβ oligomers may seem contradictory until size and conformation are taken into account. In this review, we will discuss Aβ oligomers and their toxicity in relation to size and conformation as well as their influence on inflammation and the potential of Aβ oligomer immunotherapy.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Immunotherapy